[go: up one dir, main page]

HK1116806A1 - Antibodies, antibody fragments and scfv binding to post-translationally modified neurotrophins - Google Patents

Antibodies, antibody fragments and scfv binding to post-translationally modified neurotrophins

Info

Publication number
HK1116806A1
HK1116806A1 HK08107507.3A HK08107507A HK1116806A1 HK 1116806 A1 HK1116806 A1 HK 1116806A1 HK 08107507 A HK08107507 A HK 08107507A HK 1116806 A1 HK1116806 A1 HK 1116806A1
Authority
HK
Hong Kong
Prior art keywords
antibodies
post
antibody fragments
translationally modified
scfv binding
Prior art date
Application number
HK08107507.3A
Other languages
English (en)
Inventor
Luis Barbeito
Mariana Pehar
Patricia Cassina
Pedro M Alzari
Original Assignee
Pasteur Institut
Instituto De Investigaciones Biologicas Clemente Estable
Facultad De Medicina Universidad De La Republica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Instituto De Investigaciones Biologicas Clemente Estable, Facultad De Medicina Universidad De La Republica filed Critical Pasteur Institut
Publication of HK1116806A1 publication Critical patent/HK1116806A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
HK08107507.3A 2006-07-24 2008-07-08 Antibodies, antibody fragments and scfv binding to post-translationally modified neurotrophins HK1116806A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06291195A EP1882697B1 (en) 2006-07-24 2006-07-24 Antibodies, antibody fragments and scFv binding to post-translationally modified neurotrophins

Publications (1)

Publication Number Publication Date
HK1116806A1 true HK1116806A1 (en) 2009-01-02

Family

ID=37075006

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08107507.3A HK1116806A1 (en) 2006-07-24 2008-07-08 Antibodies, antibody fragments and scfv binding to post-translationally modified neurotrophins

Country Status (11)

Country Link
US (2) US20100055109A1 (xx)
EP (2) EP1882697B1 (xx)
JP (1) JP5528803B2 (xx)
AR (1) AR062038A1 (xx)
AT (1) ATE465179T1 (xx)
BR (1) BRPI0714545A2 (xx)
CA (1) CA2657563A1 (xx)
DE (1) DE602006013809D1 (xx)
HK (1) HK1116806A1 (xx)
UY (1) UY30501A1 (xx)
WO (1) WO2008012049A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE465179T1 (de) * 2006-07-24 2010-05-15 Pasteur Institut Antikörper, antikörperfragmente und scfv die an posttranslational modifizierte neurotrophine binden
WO2012033916A1 (en) * 2010-09-08 2012-03-15 Southern Illinois University Edwardsville Method for treating chronic pain
US8911734B2 (en) 2010-12-01 2014-12-16 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
GB201214007D0 (en) * 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
JP2020507350A (ja) 2017-02-10 2020-03-12 ヴィヴィババ インコーポレイテッド 組換え神経成長因子のための組成物及び方法
AU2019243155A1 (en) * 2018-03-27 2020-10-15 Factor Bioscience Inc. Nucleic acid-based therapeutics

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
KR100261941B1 (ko) 1994-07-13 2000-07-15 나가야마 오사무 사람의 인터루킨-8에 대한 재구성 사람항체
US6068040A (en) 1998-07-24 2000-05-30 Alpine Overhead Doors, Inc. Slat edge retainer for overhead rolling doors
EP1500399A1 (en) 2003-07-24 2005-01-26 Institut Pasteur Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative deseases
ATE465179T1 (de) * 2006-07-24 2010-05-15 Pasteur Institut Antikörper, antikörperfragmente und scfv die an posttranslational modifizierte neurotrophine binden

Also Published As

Publication number Publication date
US9328163B2 (en) 2016-05-03
JP5528803B2 (ja) 2014-06-25
EP1882697B1 (en) 2010-04-21
ATE465179T1 (de) 2010-05-15
EP2046823B1 (en) 2012-11-21
US20140178384A1 (en) 2014-06-26
EP1882697A1 (en) 2008-01-30
AR062038A1 (es) 2008-08-10
EP2046823A1 (en) 2009-04-15
BRPI0714545A2 (pt) 2013-05-14
DE602006013809D1 (de) 2010-06-02
CA2657563A1 (en) 2008-01-31
JP2010501475A (ja) 2010-01-21
WO2008012049A1 (en) 2008-01-31
UY30501A1 (es) 2009-04-30
US20100055109A1 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
HK1116806A1 (en) Antibodies, antibody fragments and scfv binding to post-translationally modified neurotrophins
HRP20190312T1 (hr) Vežući proteini, uključujući protutijela, derivate protutijela i fragmente protutijela, koji se specifično vežu na cd154 i njihova upotreba
IL205545A0 (en) Monoclonal antibody capable of binding to anexelekto, and use thereof
IL240245A (en) 5t4 antibodies and their uses
IL198592A0 (en) Tes7 and antibodies that bind thereto
HK1194395A1 (zh) 抗體及其製備和使用方法
IL194995A0 (en) Modified humanised anti-interleukin-18 antibodies
AU2008225994B2 (en) Monoclonal human tumor-specific antibody
IL220622A0 (en) Monoclonal antibodies against activated and unactivated protein c
IL236237A (en) Tmem154 antibodies and their segments and uses
EP2183366A4 (en) IMMUNOGENIC POLYPEPTIDES AND MONOCLONAL ANTIBODIES
EP2281004A4 (en) PROSTATE-SPECIFIC MEMBRANANT ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
HK1158977A1 (zh) 抗膜鐵轉運蛋白 單克隆抗體及其用途
IL208188A0 (en) Compositions comprising antibodies or antibody fragments

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150724